146 related articles for article (PubMed ID: 20585121)
1. Synergy of caspofungin with human polymorphonuclear granulocytes for killing Candida albicans.
Tullio V; Mandras N; Scalas D; Allizond V; Banche G; Roana J; Greco D; Castagno F; Cuffini AM; Carlone NA
Antimicrob Agents Chemother; 2010 Sep; 54(9):3964-6. PubMed ID: 20585121
[TBL] [Abstract][Full Text] [Related]
2. Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes.
Frank U; Greiner M; Engels I; Daschner FD
Eur J Clin Microbiol Infect Dis; 2004 Sep; 23(9):729-31. PubMed ID: 15300456
[TBL] [Abstract][Full Text] [Related]
3. Candida albicans infections in renal transplant recipients: effect of caspofungin on polymorphonuclear cells.
Allizond V; Banche G; Giacchino F; Merlino C; Scalas D; Tullio V; Garneri G; Mandras N; Roana J; Cuffini AM
Antimicrob Agents Chemother; 2011 Dec; 55(12):5936-8. PubMed ID: 21968354
[TBL] [Abstract][Full Text] [Related]
4. Role of caspofungin in restoring the impaired phagocyte-dependent innate immunity towards Candida albicans in chronic haemodialysis patients.
Scalas D; Banche G; Merlino C; Giacchino F; Allizond V; Garneri G; Patti R; Roana J; Mandras N; Tullio V; Cuffini AM
Int J Antimicrob Agents; 2012 Jan; 39(1):73-6. PubMed ID: 22055531
[TBL] [Abstract][Full Text] [Related]
5. Five-minute exposure to caspofungin results in prolonged postantifungal effects and eliminates the paradoxical growth of Candida albicans.
Shields RK; Nguyen MH; Press EG; Clancy CJ
Antimicrob Agents Chemother; 2011 Jul; 55(7):3598-602. PubMed ID: 21537017
[TBL] [Abstract][Full Text] [Related]
6. Caspofungin resistance in Candida albicans: genetic factors and synergistic compounds for combination therapies.
Perrine-Walker F
Braz J Microbiol; 2022 Sep; 53(3):1101-1113. PubMed ID: 35352319
[TBL] [Abstract][Full Text] [Related]
7. Difference in killing activity of caspofungin and paradoxical growth between Candida albicans and C. krusei clinical isolates in different media.
Varga I; Sóczó G; Kardos G; Kemény-Beke A; Kelentey B; Márton I; Majoros L
J Chemother; 2009 Feb; 21(1):36-41. PubMed ID: 19297270
[TBL] [Abstract][Full Text] [Related]
8. The echinocandin caspofungin impairs the innate immune mechanism against Candida parapsilosis.
van Asbeck EC; Hoepelman AI; Scharringa J; Verhoef J
Int J Antimicrob Agents; 2009 Jan; 33(1):21-6. PubMed ID: 18774697
[TBL] [Abstract][Full Text] [Related]
9. In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms.
Sarkar S; Uppuluri P; Pierce CG; Lopez-Ribot JL
Antimicrob Agents Chemother; 2014; 58(2):1183-6. PubMed ID: 24217700
[TBL] [Abstract][Full Text] [Related]
10. Emodin Reduces the Activity of (1,3)-
Janeczko M
Pol J Microbiol; 2018; 67(4):463-470. PubMed ID: 30550232
[TBL] [Abstract][Full Text] [Related]
11. Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum.
Kovács R; Gesztelyi R; Perlin DS; Kardos G; Domán M; Berényi R; Majoros L
Mycopathologia; 2014 Oct; 178(3-4):197-206. PubMed ID: 25118874
[TBL] [Abstract][Full Text] [Related]
12. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms.
Delattin N; De Brucker K; Vandamme K; Meert E; Marchand A; Chaltin P; Cammue BP; Thevissen K
J Antimicrob Chemother; 2014 Apr; 69(4):1035-44. PubMed ID: 24284780
[TBL] [Abstract][Full Text] [Related]
13. Highly Dynamic and Specific Phosphatidylinositol 4,5-Bisphosphate, Septin, and Cell Wall Integrity Pathway Responses Correlate with Caspofungin Activity against Candida albicans.
Badrane H; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2016 Jun; 60(6):3591-600. PubMed ID: 27021331
[TBL] [Abstract][Full Text] [Related]
14. Frequency of paradoxical effect with caspofungin in Candida albicans.
Stevens DA
Eur J Clin Microbiol Infect Dis; 2009 Jun; 28(6):717. PubMed ID: 19130103
[No Abstract] [Full Text] [Related]
15. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.
Desnos-Ollivier M; Bretagne S; Raoux D; Hoinard D; Dromer F; Dannaoui E;
Antimicrob Agents Chemother; 2008 Sep; 52(9):3092-8. PubMed ID: 18591282
[TBL] [Abstract][Full Text] [Related]
16. Trailing or paradoxical growth of Candida albicans when exposed to caspofungin is not associated with microsatellite genotypes.
Khlif M; Bogreau H; Michel-Nguyen A; Ayadi A; Ranque S
Antimicrob Agents Chemother; 2010 Mar; 54(3):1365-8. PubMed ID: 20065050
[TBL] [Abstract][Full Text] [Related]
17. Caspofungin benefit on phagocytes from patients with renal dysfunction infected with multidrug-resistant Candida glabrata.
Banche G; Mandras N; Giacchino F; Scalas D; Allizond V; Roana J; Tullio V; Garneri G; Castagno F; Merlino C; Cuffini AM
Future Microbiol; 2013 Sep; 8(9):1091-6. PubMed ID: 23834733
[TBL] [Abstract][Full Text] [Related]
18. Generation of mutants in Candida albicans with reduced susceptibility to caspofungin: influence on other antifungal products.
Soler L; Rodriguez JC; Belda S; Cremades R; Ruiz-Garcia M; Lopez P; Royo G
J Chemother; 2010 Aug; 22(4):283-4. PubMed ID: 20685636
[No Abstract] [Full Text] [Related]
19. Killing Rates of Caspofungin in 50 Percent Serum Correlate with Caspofungin Efficacy Against Candida albicans in a Neutropenic Murine Model.
Domán M; Kovács R; Kardos G; Gesztelyi R; Juhász B; Bozó A; Kardos T; Saleh Q; Majoros L
Curr Drug Deliv; 2016; 13(2):255-64. PubMed ID: 27146910
[TBL] [Abstract][Full Text] [Related]
20. Nanoscale effects of caspofungin against two yeast species, Saccharomyces cerevisiae and Candida albicans.
Formosa C; Schiavone M; Martin-Yken H; François JM; Duval RE; Dague E
Antimicrob Agents Chemother; 2013 Aug; 57(8):3498-506. PubMed ID: 23669379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
